11/25/2019 1:32:18 AM
PTC Therapeutics: FDA Granted Priority Review For NDA For Risdiplam For Spinal Muscular Atrophy Treatment
11/11/2019 1:12:08 AM
PTC Therapeutics Says Risdiplam Pivotal SUNFISH Study Meets Primary Endpoint
10/24/2019 8:25:22 AM
PTC Therapeutics Announces Results From Long-Term AADC Deficiency Gene Therapy Treatment For Sustained Improvements
10/7/2019 8:02:57 AM
PTC Establishes Strategic Collaboration With Aldevron To Support GMP Plasmid Manufacturing
9/18/2019 8:28:55 AM
PTC Therapeutics Prices Private Offering Of $250.0 Mln Of Its Convertible Senior Notes Due 2026
9/18/2019 8:28:29 AM
PTC Therapeutics Prices Public Offering Of 2.48 Mln Shares At $40.40 Per Share
9/17/2019 4:03:52 PM
PTC Therapeutics Announces Proposed Public Offering Of Common Stock
8/6/2019 4:39:11 PM
PTC Therapeutics Q2 Loss/share $0.75 Vs. Loss $0.21 Year Ago
8/5/2019 8:03:12 AM
PTC Therapeutics Signs Long-term Lease Agreement With Bristol-Myers Squibb
6/28/2019 6:45:08 AM
PTC Says CHMP Of EMA Adopted Negative Opinion On Proposed Indication Extension Of Translarna
6/3/2019 8:03:14 AM
PTC Therapeutics Promotes Emily Hill To CFO
5/7/2019 2:53:39 AM
PTC Therapeutics Announces Clinical Data From Studies Of FIREFISH And SUNFISH
4/29/2019 9:23:01 AM
Translarna Approved In Brazil For Duchenne Muscular Dystrophy
2/28/2019 4:05:58 PM
PTC Therapeutics Q4 Loss/share $0.96 Vs. Profit $0.03 Year Ago